TMEM37 and acute myeloid leukemia: To targeting PR1+ AML cells, Ma et al. developed the anti-PR1/HLA-A2-second-generation CAR T cell by using the ScFv derived from anti-PR1/HLA-A2 TCR-like antibody so-called h8F4.